Literature DB >> 26807164

Epithelial-mesenchymal transition in gastric cancer.

Lei Huang1, Ruo-Lin Wu2, A-Man Xu3.   

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide with poor prognosis for lack of early detection and effective treatment modalities. The significant influence of tumor microenvironment on malignant cells has been extensively investigated in this targeted-therapy era. Epithelial-mesenchymal transition (EMT) is a highly conserved and fundamental process that is critical for embryogenesis and some other pathophysiological processes, especially tumor genesis and progression. Aberrant gastric EMT activation could endow gastric epithelial cells with increased mesenchymal characteristics and less epithelial features, and promote cancer cell stemness, initiation, invasion, metastasis, and chemo-resistance with cellular adhesion molecules especially E-cadherin concomitantly repressed, which allows tumor cells to disseminate and spread throughout the body. Some pathogens, stress, and hypoxia could induce and aggravate GC via EMT, which is significantly correlated with prognosis. GC EMT is modulated by diverse micro-environmental, membrane, and intracellular cues, and could be triggered by various overexpressed transcription factors, which are downstream of several vital cross-talking signaling pathways including TGF-β, Wnt/β-catenin, Notch, etc. microRNAs also contribute significantly to GC EMT modulation. There are currently some agents which could suppress GC EMT, shedding light on novel anti-malignancy strategies. Investigating potential mechanisms modulating GC cell EMT and discovering novel EMT regulators will further elucidate GC biology, and may provide new biomarkers for early GC detection and potentially efficient targets for preventative and curative anti-GC intervention approaches to prevent local and distant invasions.

Entities:  

Keywords:  Epithelial-mesenchymal transition; carcinogenesis; chemo-resistance; gastric cancer; metastasis; microRNA; microenvironment; prognosis; transcription factor; tumor progression

Year:  2015        PMID: 26807164      PMCID: PMC4697696     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  133 in total

Review 1.  The ins and outs of the epithelial to mesenchymal transition in health and disease.

Authors:  M Angela Nieto
Journal:  Annu Rev Cell Dev Biol       Date:  2011-07-08       Impact factor: 13.827

Review 2.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

3.  Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity.

Authors:  Dominic Chih-Cheng Voon; Huajing Wang; Jason Kin Wai Koo; Tu Anh Pham Nguyen; Yit Teng Hor; Yeh-Shiu Chu; Kosei Ito; Hiroshi Fukamachi; Shing Leng Chan; Jean Paul Thiery; Yoshiaki Ito
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

4.  Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.

Authors:  Young A Yoo; Myoung Hee Kang; Hyun Joo Lee; Baek-hui Kim; Jong Kuk Park; Hyun Koo Kim; Jun Suk Kim; Sang Cheul Oh
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

5.  Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7.

Authors:  Yinfei Yin; Anna M Grabowska; Philip A Clarke; Elisabeth Whelband; Karen Robinson; Richard H Argent; Amanda Tobias; Rajendra Kumari; John C Atherton; Susan A Watson
Journal:  Gut       Date:  2010-06-28       Impact factor: 23.059

6.  Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.

Authors:  Z Liu; Q Li; K Li; L Chen; W Li; M Hou; T Liu; J Yang; C Lindvall; M Björkholm; J Jia; D Xu
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

7.  Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases.

Authors:  A-Man Xu; Lei Huang; Liang Zhu; Zhi-Jian Wei
Journal:  Am J Cancer Res       Date:  2014-03-01       Impact factor: 6.166

8.  RUNX3 regulates vimentin expression via miR-30a during epithelial-mesenchymal transition in gastric cancer cells.

Authors:  Zhifang Liu; Long Chen; Xinchao Zhang; Xia Xu; Huaixin Xing; Yingjie Zhang; Wenjuan Li; Han Yu; Jiping Zeng; Jihui Jia
Journal:  J Cell Mol Med       Date:  2014-01-22       Impact factor: 5.310

9.  Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.

Authors:  Paulina Grygielewicz; Barbara Dymek; Anna Bujak; Pawel Gunerka; Aleksandra Stanczak; Monika Lamparska-Przybysz; Maciej Wieczorek; Karolina Dzwonek; Daria Zdzalik
Journal:  Gastric Cancer       Date:  2014-11-19       Impact factor: 7.370

10.  Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer.

Authors:  Zhi-Yuan Xu; Qi-Ming Yu; Yi-An Du; Li-Tao Yang; Rui-Zeng Dong; Ling Huang; Peng-Fei Yu; Xiang-Dong Cheng
Journal:  Int J Biol Sci       Date:  2013-06-28       Impact factor: 6.580

View more
  92 in total

Review 1.  Clinical impact of molecular classifications in gastric cancer.

Authors:  Daniele Marrelli; Karol Polom; Alessandro Neri; Franco Roviello
Journal:  Updates Surg       Date:  2018-05-23

2.  Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.

Authors:  Yao Yang; Jianfeng Shen; Dongyi Yan; Biao Yuan; Shun Zhang; Jing Wei; Tao Du
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

3.  Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas.

Authors:  Don L Gibbons; Chad J Creighton
Journal:  Dev Dyn       Date:  2017-05-04       Impact factor: 3.780

4.  P2RX7 functions as a putative biomarker of gastric cancer and contributes to worse prognosis.

Authors:  Wang Lili; Li Yun; Wei Tingran; Wu Xia; Sun Yanlei
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-01

5.  MiR-330-3p inhibits gastric cancer progression through targeting MSI1.

Authors:  Aoran Guan; Hui Wang; Xun Li; Hui Xie; Ruotian Wang; Yankun Zhu; Ruhong Li
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

6.  PIAS1 inhibited the metastasis of gastric cancer cell by epithelial-mesenchymal transition regulation within the inflammatory microenvironment.

Authors:  Xiaoyu Wang; Libing Wang; Yan Xu; Guohua Zhang; Yunlin Wu; Ping Chen
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

7.  Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Cheng-Hao Wang; Xiao-Dong Zhu; De-Ning Ma; Hui-Chuan Sun; Dong-Mei Gao; Ning Zhang; Cheng-Dong Qin; Yuan-Yuan Zhang; Bo-Gen Ye; Hao Cai; Wen-Kai Shi; Man-Qin Cao; Zhao-You Tang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  Targeting of sonic hedgehog-Gli signaling: A potential therapeutic target for patients with breast cancer.

Authors:  Lingqin Song; Weifeng Wang; Di Liu; Yang Zhao; Jianjun He; Xijing Wang; Zhijun Dai; Huimin Zhang; Xiao Li
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 9.  Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors:  Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

10.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.

Authors:  Xue Liu; Qian Chen; Xu-Gang Hu; Xian-Chao Zhang; Ti-Wei Fu; Qing Liu; Yan Liang; Xi-Long Zhao; Xia Zhang; Yi-Fang Ping; Xiu-Wu Bian
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.